# Children's Oncology Group: Phase 3 study closed enrollment, 391 enrolled (Ganglioneuroblastoma, Localized Resectable Neuroblastoma)

**Score:** 55/100

| Field | Value |
|---|---|
| Sponsor | Children's Oncology Group |
| Sponsor type | Research network |
| Study | Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma |
| NCT ID | NCT02176967 |
| Phase | Phase 3 |
| Status | active not recruiting |
| Conditions | Ganglioneuroblastoma; Localized Resectable Neuroblastoma; Localized Unresectable Neuroblastoma; Neuroblastoma |
| Intervention types | procedure, drug, other |
| Target enrollment | 391 |
| Site countries | United States, Australia, Canada, New Zealand, Puerto Rico, Saudi Arabia |
| Posted | 2014-06-27 |
| Planned start | 2014-08-08 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-13 |
| Last update posted | 2026-10-13 |

## Why this score
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 3: multi-site, larger budget.
- 391 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT02176967). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.